Sartorius AG (DE:SRT)
XETRA:SRT
Want to see DE:SRT full AI Analyst Report?
SRT Stock Chart & Stats
€194.40
€1.00(0.53%)
At close: 4:00 PM EST
€194.40
€1.00(0.53%)
Day’s Range― - ―
52-Week Range€145.40 - €208.00
Previous CloseN/A
Volume213.00
Average Volume (3M)5.04K
Market Cap
€14.29B
Enterprise Value€20.65B
Total Cash (Recent Filing)€573.80M
Total Debt (Recent Filing)€4.30B
Price to Earnings (P/E)98.1
Beta1.41
Next Earnings
Jul 23, 2026EPS Estimate
1.36Next Dividend Ex-DateN/A
Dividend Yield0.39%
Share Statistics
EPS (TTM)2.35
Shares Outstanding37,440,000
10 Day Avg. Volume4,524
30 Day Avg. Volume5,035
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)6.31
Price to Sales (P/S)4.82
P/FCF Ratio79.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€246.00Price Target Upside26.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)5.4
Revenue Forecast (FY)€3.74B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueThe business model centers on consumables and services that are repeatedly purchased after initial equipment adoption. This installed-base + repeat-consumables dynamic produces durable, recurring revenue streams, improving revenue visibility and resilience versus one-off equipment cycles.
Strong Revenue Rebound And Gross MarginA sharp TTM revenue rebound alongside a ~46% gross margin indicates improving demand and a favorable product/mix profile. Sustained top-line recovery with healthy gross margins supports operating leverage potential and the ability to absorb fixed costs over time.
Positive Operating And Free Cash FlowConsistent operating cash generation and positive FCF provide funding for capex, R&D, and debt reduction without relying solely on equity markets. Over the medium term this cash flow base enables reinvestment in consumables growth and service expansion.
Bears Say
Compressed Net MarginNet margin near 4.4% is well below prior-cycle levels, limiting retained earnings and shareholder returns. Persistently depressed profitability reduces buffer against demand slowdowns, constrains reinvestment capacity, and makes durable margin recovery a key execution risk.
Meaningful Leverage On Balance SheetElevated debt-to-equity (~1.65x) limits financial flexibility and increases sensitivity to interest costs and macro shocks. With modest ROE and compressed margins, leverage constrains M&A, aggressive capex, or dividend increases until earnings and cash conversion reliably improve.
Weak Cash ConversionLow FCF-to-net-income and weak operating cash coverage point to working-capital or timing issues that make earnings less reliable as a cash source. This hampers predictable deleveraging and raises the bar for sustainable capital allocation despite reported positive FCF.
Sartorius News
SRT FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest stock price was €145.40 and its highest was €208.00 in the past 12 months.
What is Sartorius AG’s market cap?
Sartorius AG’s market cap is €14.29B.
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Jul 23, 2026 which is in 40 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Apr 23, 2026. The company reported €1.2 earnings per share for the quarter, missing the consensus estimate of €1.284 by -€0.084.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Undervalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.73 which represents an annual dividend yield of 0.39%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is 1.36.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €1.2 in its last earnings report, missing expectations of €1.284. Following the earnings report the stock price went down -10.345%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in DE:SRT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sartorius Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€246.00 (26.54% Upside)
€246.00 (26.54% Upside)
Insider Transactions
Bought Shares
Worth €115.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.06%
12-Months-Change
Fundamentals
Return on Equity
6.05%
Trailing 12-Months
Asset Growth
-2.38%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius AG, founded in Göttingen, Germany in 1870, is a global supplier of advanced bioprocess solutions, laboratory products, and associated services. The company's diverse portfolio encompasses several critical areas: For biosensing and detection, it provides biosensors, compliance instruments, system software, label-free detection technologies, and SPR systems. In cell analysis, Sartorius offers live-cell analysis platforms, flow cytometry systems, and specialized cell analysis reagents and consumables. Its media and reagent segment includes a wide array of formulations for antibody and recombinant protein production, viral vaccines, regenerative medicine, and stem cell cultivation, along with downstream buffers, microcarriers, strong acids, bases, alcohols, and detergents. The company manufactures various bioreactor systems, from multi-parallel and benchtop units to single-use, stainless steel, cell culture, and microbial bioreactors, all supported by dedicated software applications. Its extensive filtration product line features membranes, blotting products, filter papers, and glass and quartz microfibre products, alongside a comprehensive range of filtration devices for ultrafiltration, sterile filtration, harvesting, analytical and diagnostic sample preparation, particle analysis, pharmaceutical applications, protein/DNA concentration, venting, clarification, and membrane chromatography. Sartorius also delivers solutions for process filtration, process chromatography, fluid management, and cutting-edge process analytical technology with data analytics. Complementary laboratory equipment includes industrial microbiology systems, water purification units, precision weighing and pipetting/dispensing systems, OEM components, and centrifuges. Beyond its products, Sartorius provides essential services such as bioprocess development and engineering, protein expression system optimization, media and process development, comprehensive testing, instrument support, and validation. These offerings primarily serve the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industrial sectors across the globe.
SRT Stock 12 Month Forecast
Average Price Target
€246.00
▲(26.54% Upside)
Technical Analysis
Evonik
―
GEA Group AG
―
Gerresheimer
―
Pfeiffer Vacuum Technology
―
STRATEC Biomedical
―
Options Prices
Currently, No data available
---